UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

1255P da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer

Annals of oncology, 2022-09, Vol.33, p.S1121

2022

Link zum Volltext

Verfügbarkeit prüfen

2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma

Annals of oncology, 2023-10, Vol.34, p.S1170-S1170

2023

Link zum Volltext

Verfügbarkeit prüfen

1600P Low dose pembrolizumab is effective in the treatment of advanced non-small cell lung cancer (NSCLC) with reduced cost

Annals of oncology, 2020-09, Vol.31, p.S965-S965

2020

Link zum Volltext

Verfügbarkeit prüfen

146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study

Annals of oncology, 2023-11, Vol.34, p.S1530

2023

Link zum Volltext

Verfügbarkeit prüfen

82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

Annals of oncology, 2023-11, Vol.34, p.S1498

2023

Link zum Volltext

Verfügbarkeit prüfen

1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases

Annals of oncology, 2023-10, Vol.34, p.S869-S869

2023

Link zum Volltext

Verfügbarkeit prüfen

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

Annals of oncology, 2022-09, Vol.33, p.S748

2022

Link zum Volltext

Verfügbarkeit prüfen

40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies

Annals of oncology, 2021-03, Vol.32, p.S17-S17

2021

Link zum Volltext

Verfügbarkeit prüfen

Water/Carbon Dioxide Phase Equilibria Using Thermodynamic Perturbation Theory

Journal of applied sciences (Asian Network for Scientific Information), 2014-11, Vol.14 (22), p.3055-3062

2014

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

Annals of oncology, 2020-02, Vol.31 (2), p.246-256

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup

Annals of oncology, 2023-11, Vol.34, p.S1502-S1503

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2016-12, Vol.27 (12), p.2210-2215

2016

Link zum Volltext

Verfügbarkeit prüfen

112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study

Annals of oncology, 2020-11, Vol.31, p.S1284-S1285

2020

Link zum Volltext

Verfügbarkeit prüfen

559P - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group

Annals of oncology, 2019-10, Vol.30, p.v211-v211

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)

Annals of oncology, 2019-10, Vol.30, p.v174

2019

Link zum Volltext

Verfügbarkeit prüfen

463P - Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)

Annals of oncology, 2019-10, Vol.30, p.v174-v174

2019

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group

Annals of oncology, 2019-10, Vol.30, p.v211

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii141

2018

Link zum Volltext

Verfügbarkeit prüfen

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

Annals of oncology, 2018-10, Vol.29, p.viii720-viii720

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-02, Vol.29 (2), p.526-526

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome and prognostic factors for patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS)

Annals of oncology, 2017-11, Vol.28, p.x40-x40

2017

Link zum Volltext

Verfügbarkeit prüfen

RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity

Annals of oncology, 2016-10, Vol.27, p.vi122-vi122

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Annals of oncology, 2011-11, Vol.22 (11), p.2516-2522

2011

Link zum Volltext

Verfügbarkeit prüfen

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

ESMO open, 2024-02, Vol.9 (2), p.102226-102226, Article 102226

2024

Link zum Volltext

Verfügbarkeit prüfen

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

European journal of cancer supplements, 2008, Vol.6 (12), p.130-130

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(51)
Tagungsberichte
(2)

Sprache

Englisch
(53)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(17)
Humans
(15)
Female
(11)
Oncology
(8)
Male
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Adult
(5)
Technology
(5)
Aged
(4)
Engineering
(4)
Genetics & Heredity
(4)
Middle Aged
(4)
Adolescent
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Medical Genetics
(3)
Neoplasm Staging
(3)
Pharmacokinetics
(3)
Physiological Aspects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1255P da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer

2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma

1600P Low dose pembrolizumab is effective in the treatment of advanced non-small cell lung cancer (NSCLC) with reduced cost

146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study

82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies

Water/Carbon Dioxide Phase Equilibria Using Thermodynamic Perturbation Theory

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study

559P - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group

Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)

463P - Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)

Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group

Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Clinical outcome and prognostic factors for patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS)

RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

Suchergebnisse filtern